ChartRow logo
Data provided bySource: Twelve Data
UTHR
$584.10-0.64%
as of close, Nov 17, 2026
☾ AH $584.10 -0.64%
PeersNBIXZTSVTRSTAKRDYHLN
Share this page

UTHR — United Therapeutics Corporation price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
Data provided bySource: Twelve Data
What would $1,000 invested in UTHR be worth today? →
UTHR returns: By year · By month · By week · Trailing

Price data

Price
$584.10
YTD price return
+19.88%
YTD total return
+19.88%
Market cap
24.9B
Enterprise value
22.8B
Shares outstanding
42.6M
52W low
$455.63
52W high
$614.23
From 52W high
-4.91%
From 52W low
+28.20%
52W range
81%$456–$614
Beta
0.56

Volume

Rel volume
0.68×
30D volume
596.2K
30D $ vol
339.3M

Insider trading

Insider net 1W
−$16.8M
Insider net 1M
−$116.9M
Insider net 3M
−$344.2M
Insider net 1Y
−$1.27B

Form 4 transactions by trade date, as filed; latest on file 2026-11-16.

Fundamentals

Sales (ttm)
3.2B
Sales/share
$74.84
EPS (ttm)
$26.53
FCF (ttm)
867.2M
FCF/share
$20.36
Book value/share
$147.36
Net margin
38.61%
ROE
19.61%
ROA
17.50%
Current ratio
4.61

Growth (CAGR, ttm) · 10Y

Sales
+1.89%+13.08%+14.01%+7.17%
Net income
-3.22%+11.00%+21.63%+5.69%
FCF
-22.72%+4.30%+12.22%+6.76%
Shares
-1.09%-3.23%-1.11%+0.04%

Per-share growth (CAGR, ttm) · 10Y

EPS
+0.49%+13.46%+21.75%+5.99%
Sales/share
+3.01%+16.85%+15.29%+7.13%
FCF/share
-21.87%+7.78%+13.48%+6.72%
Book value/share
-3.72%+6.63%+11.63%+13.02%
Price
+23.79%+36.63%+23.98%+15.94%
Total return
+23.79%+36.63%+23.98%+15.94%

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
22.0×
P/OI (ttm)
18.8×
Fwd P/E
16.9×
P/S (ttm)
7.8×
P/B (mrq)
4.0×
P/FCF (ttm)
28.7×
EV/EBITDA (fy)
16.1×
EV/Sales (ttm)
7.2×
FCF yield (ttm)
3.49%
Buyback yield (realized, 1y)
1.09%
Shareholder yield (realized, 1y)
1.09%
Buyback yield (cash, ttm)
8.04%
Shareholder yield (cash, ttm)
8.04%

Vs own 10Y history

P/E
97th
P/OI
93rd
P/S
99th
P/B
97th
P/FCF
99th

Bar = where today’s multiple sits in UTHR’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-17#

Data provided bySource: Twelve Data
1D
-0.64%
5D
-0.77%
1M
+9.56%
3M
+14.87%
YTD
+19.88%
1Y
+23.77%
5Y
+192.91%
1D
-0.64%
5D
-0.77%
1M
+9.56%
3M
+14.87%
YTD
+19.88%
1Y
+23.77%
5Y
+192.91%

Fundamentals#

Revenue

5Y CAGR +16.5%10Y CAGR +8.1%YoY +4.1%
$3.2B TTM$832.5M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y CAGR +20.2%10Y CAGR +7.9%YoY −20.8%
$1.3B TTM$307.8M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y CAGR +19.3%10Y CAGR +8.2%YoY −20.3%
$26.53 TTM$5.71 Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y CAGR +8.4%10Y CAGR +12.1%YoY −64.2%
$867.2M TTM$125.8M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

TTM: operating cash flow $1.4B, capex −$562.4M

Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Q3 2026: operating cash flow $306.5M, capex −$180.7M

Shares (diluted)

5Y +7.4%10Y −6.4%YoY −4.2%
46.4M TTM45.3M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y CAGR +21.0%10Y CAGR +7.4%YoY −23.6%
$1.2B TTM$258.6M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Full UTHR financials →

About United Therapeutics#

Data provided bySource: Twelve Data

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for chronic and life-threatening conditions, with particular expertise in pulmonary arterial hypertension. Its current portfolio includes Tyvaso DPI and Tyvaso inhalation solution, Remodulin injection, Orenitram extended-release tablets, and Adcirca tablets, which address different treatment needs within pulmonary vascular disease. The company also markets Unituxin, a therapy used in the treatment of high-risk neuroblastoma. United Therapeutics combines pharmaceutical research, manufacturing, regulatory operations, and specialized commercial support to serve patients, healthcare professionals, hospitals, and specialty pharmacies. Its business is centered on rare and serious diseases where ongoing treatment and differentiated delivery methods are important, including inhaled, injectable, and oral formulations. The company also operates in regenerative medicine through technologies and programs related to organ transplantation and the development of organs suitable for clinical use. United Therapeutics Corporation therefore occupies a specialized role in biotechnology, linking innovative drug development with advanced approaches to address critical shortages in transplantable organs.

Silver Spring, MD·1,400 employees·Drug Manufacturers - Specialty & Generic·unither.com·As of Oct 28, 2026

Recent filings#

All filings and insider trades →

ETFs holding UTHR#

26 of the 193 ETFs ChartRow carries live hold UTHR. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

FundNameFiled weight
IBBiShares Biotechnology ETF1.7%
XBISPDR S&P Biotech ETF0.9%
IJHiShares Core S&P Mid-Cap ETF0.6%
MDYSPDR S&P MidCap 400 ETF Trust0.6%
VBKVanguard Small-Cap Growth ETF0.3%
COWZPacer US Cash Cows 100 ETF0.3%
VBVanguard Small-Cap ETF0.3%
VHTVanguard Health Care ETF0.3%
TickerName1M1D
LLYEli Lilly and Company+12.61%-1.13%
JNJJohnson & Johnson+9.05%-1.36%
ABBVAbbVie Inc.+2.59%-0.59%
MRKMerck & Co. Inc.-1.77%-0.75%
UNHUnitedHealth Group Incorporated Common Stock (DE)-2.93%-5.42%
NVSNovartis AG+5.65%-0.67%
TMOThermo Fisher Scientific Inc.-0.47%-0.66%
AMGNAmgen Inc.+5.88%-0.95%